Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
Volatility and Risk
Xeris Biopharma has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Amylyx Pharmaceuticals has a beta of -0.16, meaning that its share price is 116% less volatile than the S&P 500.
Earnings & Valuation
This table compares Xeris Biopharma and Amylyx Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | 3.69 | $550,000.00 | $0.06 | 104.00 |
| Amylyx Pharmaceuticals | $87.37 million | 16.56 | -$144.74 million | ($1.50) | -8.67 |
Xeris Biopharma has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xeris Biopharma and Amylyx Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | 3.81% | 735.00% | 3.24% |
| Amylyx Pharmaceuticals | N/A | -55.69% | -50.73% |
Institutional & Insider Ownership
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings for Xeris Biopharma and Amylyx Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 2 | 4 | 0 | 2.43 |
| Amylyx Pharmaceuticals | 1 | 2 | 8 | 1 | 2.75 |
Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 73.08%. Amylyx Pharmaceuticals has a consensus target price of $23.00, indicating a potential upside of 76.79%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Amylyx Pharmaceuticals is more favorable than Xeris Biopharma.
Summary
Xeris Biopharma beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
